S

Scholar Rock Holding Corp
D

SRRK

43.970
USD
-0.83
(-1.85%)
مغلق
حجم التداول
31,778
الربح لكل سهم
-3
العائد الربحي
-
P/E
-19
حجم السوق
4,116,249,395
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    C
    CHWY
    1.175
    (3.48%)
    34.910 USD
    F
    FATE
    -0.03500
    (-2.07%)
    1.65500 USD
    G
    GH
    -0.650
    (-2.05%)
    31.020 USD
    N
    NVTA
    0
    (0%)
    0.000000 USD
    P
    PSTG
    -0.600
    (-0.93%)
    63.800 USD
    R
    RDFN
    0.02000
    (0.23%)
    8.54000 USD
    R
    RGEN
    0.960
    (0.66%)
    145.530 USD
    T
    TDOC
    -0.31000
    (-3.28%)
    9.14000 USD
    T
    TWST
    0.110
    (0.23%)
    48.100 USD
    المزيد
الأخبار
المقالات

العنوان: Scholar Rock Holding Corp

القطاع: Healthcare
الصناعة: Biotechnology
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGF1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.